These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20653794)

  • 21. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
    Bevilacqua M; Dominguez LJ; Barbagallo M
    J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesterol, vitamin D and cardiovascular prevention in HIV patients treated with antiretroviral therapy.
    Mascitelli L; Pezzetta F; Goldstein MR
    Int J Cardiol; 2011 Feb; 146(3):441-2. PubMed ID: 21094536
    [No Abstract]   [Full Text] [Related]  

  • 24. What happens to children growing up with HIV infection? It's time for a HAART to heart.
    Viganò A; Pattarino G; Cerini C; Zuccotti GV
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):495-8. PubMed ID: 19485788
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
    Iloeje UH; Yuan Y; L'italien G; Mauskopf J; Holmberg SD; Moorman AC; Wood KC; Moore RD
    HIV Med; 2005 Jan; 6(1):37-44. PubMed ID: 15670251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences.
    Neumann T; Woiwod T; Neumann A; Ross B; Von Birgelen C; Volbracht L; Brockmeyer NH; Gerken G; Erbel R
    Eur J Med Res; 2004 Feb; 9(2):55-60. PubMed ID: 15090290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Also consider cardiovascular risk. Every HIV patient "his" HAART].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():58-60. PubMed ID: 19031565
    [No Abstract]   [Full Text] [Related]  

  • 32. Endothelial function in HIV-infected patients with low or mild cardiovascular risk.
    Blanco JJ; García IS; Cerezo JG; de Rivera JM; Anaya PM; Raya PG; García JG; López JR; Hernández FJ; Rodríguez JJ
    J Antimicrob Chemother; 2006 Jul; 58(1):133-9. PubMed ID: 16702174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of cardiovascular disease in HIV-infected patients.
    Das S
    J Antimicrob Chemother; 2010 Mar; 65(3):386-9. PubMed ID: 20026610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sex and race on lipodystrophy pathogenesis.
    Nolan D; Mallal S
    J HIV Ther; 2001 May; 6(2):32-6. PubMed ID: 11501201
    [No Abstract]   [Full Text] [Related]  

  • 35. Highly active antiretroviral therapy and the cardiovascular system: the heart of the matter.
    Barbaro G
    Pharmacology; 2003 Dec; 69(4):177-9. PubMed ID: 14624056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chronic hepatitis C in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Halota W; Pawłowska M
    Przegl Epidemiol; 2002; 56 Suppl 5():41-5. PubMed ID: 15553071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
    Magen E; Elbirt D; Sthoeger Z
    Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growing up with perinatal HIV infection: time for a HAART to heart.
    Siberry GK; Joyner M; Hutton N
    J Pediatr; 2008 Oct; 153(4):456-7. PubMed ID: 18847617
    [No Abstract]   [Full Text] [Related]  

  • 39. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients.
    de Castro IF; Micheloud D; Berenguer J; Guzmán-Fulgencio M; Catalán P; Miralles P; Alvarez E; López JC; Cosín J; Lorente R; Muñoz-Fernández MA; Resino S
    AIDS; 2010 Aug; 24(13):2059-67. PubMed ID: 20616694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.